Evommune Inc, a clinical-stage biotechnology company, on Friday reported additional positive data from its Phase 2 trial of EVO756 in adults with chronic inducible urticaria (CIndU)

This data was revealed in a late-breaker oral presentation at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, France.

Evommune previously announced top-line data from the trial in May 2025.

The Phase 2 trial involved 30 adults with symptomatic dermographism (common CIndU subtype), with patients serving as their own control. EVO756 was administered orally for four weeks at either 300mg once daily (QD) or 50mg twice daily (BID). Efficacy was measured by FricTest provocation scores and Pruritus Numeric Rating Scale (NRS), and safety assessments were performed at each visit.

Data from the study revealed robust clinical activity in both dose groups, with clinical responses observed in 93% of patients at just four weeks in either FricTest score or Pruritus-NRS. According to the findings, 70% of patients demonstrated an improvement in FricTest score at just four weeks, with 30% of patients achieving a complete response. Reduced Pruritus-NRS was observed at week 4 in 78% of patients, with a greater than 4-point reduction observed in 41%.

There were improvements seen in both Pruritus NRS and FricTest scores within one week, including three patients with complete responses.

Half (50%) of complete responders were IgE high (greatert than 100 IU/mL), demonstrating that clinical improvement was not limited to IgE low subjects.

The product was also well-tolerated.

Evommune is developing EVO756 with the intent of producing the first MRGPRX2-targeted oral treatment for chronic inflammatory diseases, including chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), with additional possible applications in neuroinflammation.